TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01509807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine sulfate or Sponsor-approved equivalent
Description: Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
Study: NCT04088253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical herneal repair
Description: reduction of the herneal content an repair of the defect with IPOM
Study: NCT03135795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: Patients received intravenous dexmedetomidine 1μg/Kg for induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Patients received intravenous propofol 2mg/Kg for induction, and received intavenous pump of propofol (0.3-0.6mg/kg/h) for maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Patients received intravenous rocuronium 0.6mg/Kg for induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Patients received inhalation of sevoflurane (1-2%) for maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parecoxib
Description: Parecoxib 40mg was given single intravenously before incision.
Study: NCT02981472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K Antagonist (VKA)
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Molecular Weight Heparin (LMWH)
Description: Specified dose on specified days
Study: NCT04335825

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacotrabeculectomy
Description: combined antiglaucoma procedure: trabeculectomy with phacoemulsification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ExPress antiglaucoma surgery combined with phacoemulsification
Description: combined antiglaucoma procedure: ExPress device implantation with phacoemulsification
Study: NCT02107664

Intervention type: RADIATION
Intervention: Palliative RT for bone cancer pain
Study: NCT00722605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cone-beam CT
Description: You will have the following CT scans along with the standard weekly portal images:Before treatment you will have a CT scan (a respiratory-correlated CT scan) at the time of the radiation planning, or simulation planning.During the first week of treatment - you will have 5 cone-beam CT scans at days 1 through 5 of your radiation treatment schedule.~* During the remaining weeks of treatment - you will have a cone-beam CT scan every week. Depending on the number of treatments that your study doctor has prescribed for you, the number of weekly scans can be between 3 and 7.~* For all scans, an external monitor will be used to record your breathing.~* If needed, you will be repositioned by adjusting the radiation machine's treatment couch position.
Study: NCT03351673

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: endometrial volume 2D TVS
Description: calculation the endometrial volume using 2D ultrasound and correlation the results with the pathological findings of endometrial biopsy
Study: NCT00783289

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to benralizumab (MEDI-563) injection subcutaneously on Day 0, 28, and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 25 mg
Description: Benralizumab (MEDI-563) injection 25 milligram (mg) subcutaneously on Day 0, 28, and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 100 mg
Description: Benralizumab (MEDI-563) injection 100 mg subcutaneously on Day 0, 28, and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab 200 mg
Description: Benralizumab (MEDI-563) injection 200 mg subcutaneously on Day 0, 28, and 56.
Study: NCT03952130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Degludec
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Administered SC
Study: NCT02396147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385 T2 Formulation
Description: TAK-385 T2 Formulation tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385 T2 Formulation
Description: TAK-385 T2 Formulation tablets
Study: NCT01311583

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teach Back method of patient discharge teaching
Description: Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
Study: NCT00536614

Intervention type: GENETIC
Group type: NO_INTERVENTION
Intervention: cetuximab
Description: Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.
Study: NCT02221414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin/Metformin FDC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Study: NCT02396147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385 T4 Formulation B
Description: TAK-385 T4 Formulation B tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-385 T4 Formulation C
Description: TAK-385 T4 Formulation C tablets
Study: NCT01960686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV F Antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV F Antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV F Antigen
Study: NCT02221414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study: NCT01960686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose RSV F Antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV F Antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV F Antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose RSV F Antigen

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 1 of Aluminum Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 2 of Aluminum Adjuvant
Study: NCT02602197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: After anesthetic induction, the first I.V bolus injections of 1 gr paracetamol (total amount of 100 ml) were given during 15 minutes and then repeated every 6 h until 24 h postoperative period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen
Description: After anesthetic induction, the first I.V bolus injections of 50 mg Dexketoprofen (premixed with 0.9 % sodium chloride to total amount of 100 ml) were given during 15 minutes and then repeated every 8 h until 24 h postoperative period.
Study: NCT02708173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose of Quadrivalent Influenza Virus Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: One dose of Quadrivalent Influenza Virus Vaccine
Study: NCT01384409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-3357
Description: Intravenous infusion once a day
Study: NCT01960686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 2 of Aluminum Adjuvant
Study: NCT02405962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT
Description: Four sessions of group-based ACT integrated with asthma education. Each session will compose of pediatric asthma education based on guidelines of Global Strategy for Asthma Management and Prevention Revised 2011, plus group-based Acceptance and Commitment Therapy (ACT). The goal of ACT is to enhance the psychological flexibility of the parents, enabling them to (1) become aware of their thoughts and feelings regarding their child's asthma and its management, (2) accept and adapt flexibly to challenging situations, and (3) take actions to achieve valued goals in childhood asthma management.
Study: NCT01960686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 3 of Aluminum Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 3 of Aluminum Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 4 of Aluminum Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 4 of Aluminum Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02405962

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: One session of educational talk about pediatric asthma care, as the usual care. To ensure the equivalency of the assigned sessions between groups, after attending the talk in the first week, the parents in the Control group will receive three telephone calls, starting from the second week on a weekly basis. This arrangement can also minimize the interference of the usual care naturalistically available in the study setting.
Study: NCT01960686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03985995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD 800 mg p.o
Description: cannabidiol solution 100 mg/ml 8 ml in single-dose containers for per os administration. After a washout period of at least two weeks, the treatment group will be receiving a single-dose of the placebo solution 8 ml as a second intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo p.o
Description: single dose of oral placebo solution 8 ml matched to the IMP. After a washout period of at least two weeks, the control intervention group will be receiving the cannabidiol solution 100 mg/ml 8 ml as a second intervention.
Study: NCT01454999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTI
Description: Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CTI
Description: Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
Study: NCT00962650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transgastric diagnostic peritoneoscopy with laparoscopic assistance
Description: Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
Study: NCT02530866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower glycemic targets
Description: Women will be randomized to either standard or lower glycemic targets.
Study: NCT01960686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02530866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower glycemic targets
Description: Women will be randomized to either standard or lower glycemic targets.
Study: NCT02928432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids switch
Description: Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
Study: NCT03122665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam Low dose
Description: Continuous intravenous infusion at 0.5 mg/ml for three hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam High dose
Description: Continuous intravenous infusion at 1.0 mg/ml for three hours.
Study: NCT02667834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Description: A randomized, controled trial of social cognition and interaction training ( SCIT) for patients with schizophrenia Spectrum disorders

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic education program (ETP)
Description: usual treatment ,30 hours with therapist, only discussion between patients
Study: NCT03018938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Analog Mid Mixture
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Insulin Analog
Description: Administered SC
Study: NCT04401293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Full Dose LMWH anticoagulation therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic/Intermediate Dose Enoxaparin
Description: Prophylactic/Intermediate Dose LMWH or UFH therapy
Study: NCT03679884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 10 mg
Description: Daridorexant 10 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Description: Daridorexant 25 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Description: Daridorexant 25 mg film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Description: Daridorexant 50 mg film-coated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo film-coated tablets
Study: NCT02204735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat majority of calories in the morning
Study: NCT03279978

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02204735

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eat the majority of calories in the evening
Study: NCT03228407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Confocal endomicroscopy
Description: Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.
Study: NCT03228407

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Confocal endomicroscopy
Description: Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.
Study: NCT01960686

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03576872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational
Description: Providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients for chemotherapy
Study: NCT01759303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: For subjects \> 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.~For subjects 16-17 years of age with a BSA \< 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.
Study: NCT02082184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor Based Glucose Monitoring System
Description: Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Blood Glucose Monitoring
Description: Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.~All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation.
Study: NCT03177252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: -2% lidocaine will be given

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride
Description: -Normal saline will be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: -0.5% bupivacaine will be given
Study: NCT02187640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure
Description: Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control group
Description: Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
Study: NCT02832271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUNPHENON EGCg
Description: SUNPHENON EGCg Oral, 400mg, twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00881920

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kappa CD28 T cells
Description: T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10\^7 cells/m\^2 CAR-Kappa~Group 2: 1x10\^8 cells/m\^2 CAR-Kappa~Group 3: 2x10\^8 cells/m\^2 CAR-Kappa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kappa CD28 T cells
Description: T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10\^7 cells/m\^2 CAR-Kappa~Group 2: 1x10\^8 cells/m\^2 CAR-Kappa~Group 3: 2x10\^8 cells/m\^2 CAR-Kappa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kappa CD28 T cells
Description: T cells will be given in a lymphopenic environment utilizing (as needed) lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:~Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.~Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.~ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.~T cell dosing is as follows:~Group 1: 2x10\^7 cells/m\^2 CAR-Kappa~Group 2: 1x10\^8 cells/m\^2 CAR-Kappa~Group 3: 2x10\^8 cells/m\^2 CAR-Kappa
Study: NCT03279978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Once per day (QD) on Days -1, 3, and 14. Dose groups BI 730357 200 mg fed and BI 730357 400 mg fed